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nvestigations
s There a Kink in the Wire?
e read with interest the report by Tonino et al. (1) on behalf of
he FAME (Fractional Flow Reserve [FFR] Versus Angiography
n Multivessel Evaluation) investigators. They concluded that
angiography is inaccurate in assessing the functional significance
f a coronary stenosis when compared with the FFR, not only ineverity category” (1). The FAME study, including this more
etailed analysis, provides a strong foundation for moving toward
schemia-directed stent therapy in patients with symptomatic
oronary artery disease (2,3), and we agree with this in principle.
We are concerned, however, with the lack of clarity for how the
ercent diameter stenosis was determined in this study and
hether the conclusions are related to the fallibility of angiography
r the methods of angiographic analysis. Although it is valid to
onsider a visual estimate of angiographic severity for purposes of
he FAME trial, it should be clarified if this is the case before
onclusions regarding the value of angiography are made. It is welltrialsnown that visual estimates generally overestimate lesion severity
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December 28, 2010/January 4, 2011:114–6s determined by quantitative coronary angiographic (QCA)
ethods. Furthermore, QCA lesion severity has been the standard
or determination of clinically indicated revascularization in coro-
ary stent clinical trials, on which the safety and effectiveness of
hese devices are based (4).
With this background, more detailed information on the
ngiographic analysis used in FAME becomes of interest. We did
ot find this information in any of the original FAME publica-
ions. We kindly request that the FAME investigators provide the
etails of how angiographic severity was determined. If QCA was
ot available, what methods were used to verify standardization of
eporting among investigators? We also invite the FAME inves-
igators to express their expert opinion if this additional informa-
ion would impact their conclusions (if divergent from the index
aper) and what would be the repercussions for clinical practice
nd future stent investigations, if any.
onald E. Cutlip, MD
oxana Mehran, MD
Pascal Vranckx, MD
Hartcentrum Hasselt
nterventional Cardiology and Intensive Care
tadsomvaart 11
asselt, Limburg 3500
elgium
-mail: pascal.vranckx@jessazh.be
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1). In recent randomized trials evaluating coronary revasculariza-
ion, like the COURAGE (Clinical Outcomes Utilizing Revascu-
arization and Aggressive Drug Evaluation), BARI 2D (Bypass
ngioplasty Revascularization Investigation 2 Diabetes), and
YNTAX (Synergy Between Percutaneous Coronary Intervention
ith TAXUS and Cardiac Surgery) studies, as well as in daily
ractice in most catheterization laboratories, lesions with a diam-
ter stenosis 50% based on visual estimation on the angiogram
re generally considered for revascularization (2–4).
The FAME (Fractional Flow Reserve [FFR] Versus Angiog-
aphy in Multivessel Evaluation) study was designed to reflect daily
ractice as much as possible (5,6). Therefore, coronary artery
tenoses were included in the FAME study if the operator
ndicated that such a stenosis was at least 50% on the angiogram byisual estimation, which he or she deemed to require stenting. Also
efore randomization, the operator categorized the lesions accord-
ng to visual angiographic stenosis severity into 50% to 70%, 71%
o 90%, and 91% to 100% diameter stenosis.
It is not quantitative coronary angiography (QCA), but visual
stimation on the angiogram that is mostly used in catheterization
aboratories and in trials on coronary revascularization strategies.
oreover, QCA is hampered by the same well-known shortcom-
ngs as visual angiographic estimation of stenosis severity. Several
tudies have compared QCA with FFR, all showing that QCA is
ust as inaccurate as visual estimation in predicting a lesion’s
emodynamic importance (7–9).
Because of the aforementioned arguments, we express the
pinion that the use of QCA for the selection and categorization
f stenoses in the FAME study would not have added clinically
elevant information or changed outcomes. We would like to
nderline that in patients with multivessel coronary artery disease,
oronary angiography is an inappropriate tool to identify ischemia-
roducing stenoses as detected by FFR, especially in the 50% to
0% stenosis range, by visual estimation.
ico H. J. Pijls, MD, PhD
Pim A. L. Tonino, MD, PhD
Department of Cardiology
atharina Hospital
ichelangelolaan 2
indhoven, 5623 EJ
he Netherlands
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